Rice University scientists have achieved the total synthesis of a scarce natural marine product that may become a powerful cancer-fighting agent – the molecule shishijimicin A.
A group led by world-renowned Rice chemist K.C. Nicolaou announced the successful synthesis this month in the Journal of the American Chemical Society.
The complex organic molecule was discovered in a rare sea squirt, Didemnum proliferum, more than a decade ago. Lab tests at the time proved it to be more than 1,000 times as toxic to cancer cells as the anticancer drug taxol (aka paclitaxel), but its scarcity did not provide amounts sufficient for extensive biological studies and clinical trials.
For that, chemists needed to design and develop the many steps required to synthesize the molecule, a specialty for which Nicolaou is well-known. Nicolaou, who joined Rice in 2013, is noted for achieving the first synthesis of taxol as well as the synthesis of the highly cytotoxic compound calicheamicin, which was used in the first antibody-drug conjugate (ADC) for targeted chemotherapy.
Nicolaou said shishijimicin shows just as much potential – and perhaps more – for cancer treatment via “Trojan horse”-style ADCs tuned to target specific types of cancer. “Because it’s so potent, you may only need one or two molecules to get into a cancer cell to do the job,” he said.
Such toxins kill cancer cells by cleaving their DNA or freezing their cytoskeletons to prevent them from replicating, he said.
The path to synthesis took a rapid two years because much of the groundwork had already been set by Nicolaou’s basic work three decades ago in the total synthesis of calicheamicin.
“All the fundamental science for the shishijimicin project was done in the 1990s,” he said. “What we synthesized then was too toxic to be used, but now it has revitalized the whole field because biologists and clinicians can selectively target cancer cells (with ADCs). If we hadn’t done the fundamental science so many years ago, it would have taken us so much longer to come to the same point.”
Nicolaou said his prime concern, in addition to facilitating biology and medicine, is to advance the field of synthetic chemistry. “If we don’t advance it now, we won’t be able to make the complex molecules of the future,” he said. “We have to continue to sharpen the tools of organic synthesis.”
Nicolaou said the next steps for shishijimicin are to streamline its synthesis and add chemical handles so it can be attached to antibodies for delivery to cancer cells. “We’ve established the beachhead with the first total synthesis,” he said. “Now we aim to optimize the process to make it more practical and apply it to synthesize variations of the molecule.”
Then it will be up to partner pharmaceutical companies to develop the compound for eventual clinical trials. They won’t need much, Nicolaou said. “If they have a few hundred milligrams – a fraction of a gram – they can take it to clinical trials, because it’s so potent,” he said. “And now they have hundreds of antibodies selected for different kinds of cancer. My hope is that our molecule will lead to an effective drug for personalized medicine.”
Rice postdoctoral researchers Zhaoyong Lu, James Woods and Te-ik Sohn and graduate student Ruofan Li are co-authors of the paper. Nicolaou is Rice’s Harry C. and Olga K. Wiess Professor of Chemistry.
The Cancer Prevention and Research Institute of Texas and the Welch Foundation supported the research.
RT @TXMedCenter: August is National Immunization Awareness Month. Last year, a #TMCPulse story asked: Is #Texas poised for a #measles outbr…
RT @RiceUNews: “As early childhood educators, we know that children look to us as helpers and desperately need opportunities to engage in m…
Celebrating #NHCW18, @Texas_Heart is a proud member of the @WomenHeartOrg National Hospital Alliance so that #heartdisease patients in every community have access to information, education, and patient support services. https://t.co/pQNdoz1Yag https://t.co/T95vazvZQC
.@usnews has once again recognized @MethodistHosp as one of the nation’s best in providing exceptional patient care. See how the No. 1 hospital in Texas treats patients differently. → https://t.co/AFaQv9VqNU https://t.co/RksqZehwN0
RT @bcm_careerdev: Thanks @immatics for providing @bcmhouston PhD students exposure to #immunotherapy research careers #BCMjobshadow2018 ht…
MD Anderson Cancer Center@MDAndersonNews
Diagnosed with #heartdisease and #lungcancer within weeks of each other, Everette Gardner Jr. found success in managing both, thanks to @MaraAntonoff’s guidance: https://t.co/2jeLw9mnIH #LCSM #CancerMoonshot #endcancer https://t.co/6BhrU7A9Q8
RT @abc13houston: If you’re the parent of a child with a significant health issue, back-to-school is about more than school supplies or a n…
RT @abc13houston: BACK TO SCHOOL HEALTH: Getting your child ready for school requires more than supplies. What about immunizations? Use #UT…
Headphones are showing up on back-to-school lists more and more, but could these earbuds cause permanent harm? https://t.co/gLA1azijPB #hearing
RT @UHhousing: We'll be sharing #CougarMoveIn tips all week! First things first, confirm your move-in date and time. We even have a printab…
RT @UHCOE: Who has a question for Stephanie Rice this Friday? DM or email us at email@example.com. What should @UHCOEDean McPherson ask during…
RT @UHOteam: THAT’S A WRAP! 🤩We want to thank our students and staff for making this summer so memorable!! We can’t wait to see y’all aro…
CHI St. Luke's Health@CHI_StLukes
.@USnews has ranked Baylor St. Luke’s #2 in Houston and #4 in Texas! We also rank nationally for Cardiology, Neurology & Neurosurgery, and Gastroenterology & GI Surgery, and we’ve received High Performing Hospital ratings in 10 categories. Full details at https://t.co/0lOU3I9Szu https://t.co/zsmdRp5sms
MD Anderson Cancer Center@MDAndersonNews
We are honored to receive this distinction. #besthospitals #endcancer https://t.co/xsJ6CziuQH
Join Dr. Srivaths and American Kidney Fund at noon for a webinar about kidney disease in children. Learn more: https://t.co/aMBUI5uIst https://t.co/HRSYRtq0Qe